Impact of the 2026 Dyslipidemia Guideline on ASCVD Reclassification and Statin Recommendations in MESA

BACKGROUND: The 2026 American College of Cardiology (ACC)/American Heart Association (AHA)/Multisociety Guideline on the Management of Dyslipidemia recommends the use of the PREVENT (Predicting Risk of cardiovascular disease EVENTs) equations to predict atherosclerotic cardiovascular disease (ASCVD) risk while concurrently revising previous risk-category thresholds. The impact of these reclassifications is yet to be described. OBJECTIVES: The authors characterized ASCVD reclassification and statin recommendations under the 2026 guideline, evaluated clinical events under this reclassification, and examined risk enhancement with risk enhancers and coronary artery calcium (CAC) burden. METHODS: Adults (N = 6,098) from the MESA (Multi-Ethnic Study of Atherosclerosis) were assessed, comparing the Pooled Cohort Equations (PCE) and 2013 thresholds to PREVENT with 2026 thresholds. We evaluated the degree of directional reclassification, impact on statin recommendations, and risk enhancement with biomarkers and CAC burden. RESULTS: Over a median follow-up of 10 years, 6.0% of participants had an ASCVD event. PREVENT reclassified 16.4% to a lower and 13.1% to a higher risk category as compared to the PCE. The statin recommendation under PREVENT was 50.4% compared to 55.2% under PCE. Of those who were no longer recommended for statin use, 4.9% went on to have an event. Individuals who were reclassified downward but had elevated CAC or any risk-enhancing factors had a higher event rate. CONCLUSIONS: Adherence to the 2026 guideline may lead to a small net downward reclassification of predicted ASCVD risk. Statin recommendations will fall modestly, however, not accompanied by a substantial number of subsequent events. Risk enhancers and elevated CAC identify higher risk subgroups than their PREVENT risk would suggest, emphasizing their supporting role in risk prediction.

Authors

Institutions

Publication Details

Journal
JACC Advances
Published
2026-11-13
DOI
https://doi.org/10.1016/j.jacadv.2026.103485
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Impact of the 2026 Dyslipidemia Guideline on ASCVD Reclassification and Statin Recommendations in MESA

Alain Gerald Bertoni, Robyn L. McClelland, Andrew Paul DeFilippis, Wendy S. Post et al.
5 links
JACC Advances
Lipoproteins and Cardiovascular Health
article

Impact of the 2026 Dyslipidemia Guideline on ASCVD Reclassification and Statin Recommendations in MESA

Alain Gerald Bertoni, Robyn L. McClelland, Andrew Paul DeFilippis, Wendy S. Post, Roger Scott Blumenthal, Yunbi Nam, Brittany Saldivar Murphy, M. Sims Hershey, Shi Huang
article en

Abstract

BACKGROUND: The 2026 American College of Cardiology (ACC)/American Heart Association (AHA)/Multisociety Guideline on the Management of Dyslipidemia recommends the use of the PREVENT (Predicting Risk of cardiovascular disease EVENTs) equations to predict atherosclerotic cardiovascular disease (ASCVD) risk while concurrently revising previous risk-category thresholds. The impact of these reclassifications is yet to be described. OBJECTIVES: The authors characterized ASCVD reclassification and statin recommendations under the 2026 guideline, evaluated clinical events under this reclassification, and examined risk enhancement with risk enhancers and coronary artery calcium (CAC) burden. METHODS: Adults (N = 6,098) from the MESA (Multi-Ethnic Study of Atherosclerosis) were assessed, comparing the Pooled Cohort Equations (PCE) and 2013 thresholds to PREVENT with 2026 thresholds. We evaluated the degree of directional reclassification, impact on statin recommendations, and risk enhancement with biomarkers and CAC burden. RESULTS: Over a median follow-up of 10 years, 6.0% of participants had an ASCVD event. PREVENT reclassified 16.4% to a lower and 13.1% to a higher risk category as compared to the PCE. The statin recommendation under PREVENT was 50.4% compared to 55.2% under PCE. Of those who were no longer recommended for statin use, 4.9% went on to have an event. Individuals who were reclassified downward but had elevated CAC or any risk-enhancing factors had a higher event rate. CONCLUSIONS: Adherence to the 2026 guideline may lead to a small net downward reclassification of predicted ASCVD risk. Statin recommendations will fall modestly, however, not accompanied by a substantial number of subsequent events. Risk enhancers and elevated CAC identify higher risk subgroups than their PREVENT risk would suggest, emphasizing their supporting role in risk prediction.

JACC AdvancesVol. 5(12)
Johns Hopkins University (US), University of Washington (US), Johns Hopkins Medicine (US), Wake Forest University Health Sciences (US), Wake Forest University (US), Vanderbilt University Medical Center (US)
Good health and well-being
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon